S&P 500   3,137.46 (+0.05%)
DOW   27,920.99 (+0.04%)
QQQ   204.32 (+0.12%)
AAPL   269.22 (+0.86%)
FB   200.60 (-0.37%)
MSFT   151.39 (+0.02%)
NVDA   214.53 (+1.11%)
MU   47.84 (+2.97%)
BABA   201.44 (+1.36%)
TSLA   349.18 (+2.84%)
F   9.08 (+0.67%)
NFLX   295.09 (-2.45%)
GILD   67.01 (+0.10%)
DIS   146.47 (+0.18%)
S&P 500   3,137.46 (+0.05%)
DOW   27,920.99 (+0.04%)
QQQ   204.32 (+0.12%)
AAPL   269.22 (+0.86%)
FB   200.60 (-0.37%)
MSFT   151.39 (+0.02%)
NVDA   214.53 (+1.11%)
MU   47.84 (+2.97%)
BABA   201.44 (+1.36%)
TSLA   349.18 (+2.84%)
F   9.08 (+0.67%)
NFLX   295.09 (-2.45%)
GILD   67.01 (+0.10%)
DIS   146.47 (+0.18%)
S&P 500   3,137.46 (+0.05%)
DOW   27,920.99 (+0.04%)
QQQ   204.32 (+0.12%)
AAPL   269.22 (+0.86%)
FB   200.60 (-0.37%)
MSFT   151.39 (+0.02%)
NVDA   214.53 (+1.11%)
MU   47.84 (+2.97%)
BABA   201.44 (+1.36%)
TSLA   349.18 (+2.84%)
F   9.08 (+0.67%)
NFLX   295.09 (-2.45%)
GILD   67.01 (+0.10%)
DIS   146.47 (+0.18%)
S&P 500   3,137.46 (+0.05%)
DOW   27,920.99 (+0.04%)
QQQ   204.32 (+0.12%)
AAPL   269.22 (+0.86%)
FB   200.60 (-0.37%)
MSFT   151.39 (+0.02%)
NVDA   214.53 (+1.11%)
MU   47.84 (+2.97%)
BABA   201.44 (+1.36%)
TSLA   349.18 (+2.84%)
F   9.08 (+0.67%)
NFLX   295.09 (-2.45%)
GILD   67.01 (+0.10%)
DIS   146.47 (+0.18%)
Log in

NYSE:RMD - ResMed Stock Price, Forecast & News

$149.37
+0.05 (+0.03 %)
(As of 12/10/2019 02:08 PM ET)
Today's Range
$148.79
Now: $149.37
$149.96
50-Day Range
$126.52
MA: $145.30
$150.96
52-Week Range
$90.64
Now: $149.37
$151.60
Volume11,708 shs
Average Volume451,557 shs
Market Capitalization$21.48 billion
P/E Ratio41.04
Dividend Yield1.04%
Beta0.41
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP76115210
Phone858-836-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.61 billion
Cash Flow$4.68 per share
Book Value$14.42 per share

Profitability

Net Income$404.59 million

Miscellaneous

Employees7,240
Market Cap$21.48 billion
Next Earnings Date1/23/2020 (Estimated)
OptionableOptionable

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.


ResMed (NYSE:RMD) Frequently Asked Questions

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, October 24th. Investors of record on Thursday, November 7th will be given a dividend of $0.39 per share on Thursday, December 12th. This represents a $1.56 annualized dividend and a yield of 1.04%. The ex-dividend date is Wednesday, November 6th. View ResMed's Dividend History.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its quarterly earnings data on Thursday, October, 24th. The medical equipment provider reported $0.93 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.87 by $0.06. The medical equipment provider had revenue of $681.06 million for the quarter, compared to analysts' expectations of $660.87 million. ResMed had a return on equity of 26.72% and a net margin of 15.52%. The business's revenue for the quarter was up 15.8% on a year-over-year basis. During the same period last year, the business earned $0.81 earnings per share. View ResMed's Earnings History.

When is ResMed's next earnings date?

ResMed is scheduled to release their next quarterly earnings announcement on Thursday, January 23rd 2020. View Earnings Estimates for ResMed.

What price target have analysts set for RMD?

7 Wall Street analysts have issued twelve-month price objectives for ResMed's stock. Their forecasts range from $95.00 to $140.00. On average, they expect ResMed's stock price to reach $118.33 in the next year. This suggests that the stock has a possible downside of 20.8%. View Analyst Price Targets for ResMed.

What is the consensus analysts' recommendation for ResMed?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ResMed.

Has ResMed been receiving favorable news coverage?

Headlines about RMD stock have been trending somewhat positive on Tuesday, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ResMed earned a news impact score of 1.2 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for ResMed.

Are investors shorting ResMed?

ResMed saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 2,740,000 shares, an increase of 18.6% from the October 31st total of 2,310,000 shares. Based on an average daily trading volume, of 517,200 shares, the days-to-cover ratio is currently 5.3 days. Currently, 1.9% of the company's shares are short sold. View ResMed's Current Options Chain.

Who are some of ResMed's key competitors?

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include Energy Transfer LP Unit (ET), Visa (V), Starbucks (SBUX), Netflix (NFLX), Walt Disney (DIS), Mastercard (MA), salesforce.com (CRM), Alphabet (GOOG), NVIDIA (NVDA) and AT&T (T).

Who are ResMed's key executives?

ResMed's management team includes the folowing people:
  • Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 47)
  • Mr. Robert A. Douglas, Pres & COO (Age 59)
  • Mr. Brett A. Sandercock, Chief Financial Officer (Age 52)
  • Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 60)
  • Mr. James Hollingshead, Pres of Sleep Bus. (Age 56)

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of of institutional and retail investors. Top institutional investors include WCM Investment Management LLC (5.33%), State Street Corp (4.45%), Congress Asset Management Co. MA (0.55%), Sumitomo Mitsui Trust Holdings Inc. (0.52%), Stephens Investment Management Group LLC (0.25%) and Rhumbline Advisers (0.24%). Company insiders that own ResMed stock include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Richard Sulpizio, Robert Andrew Douglas and Ronald R Taylor. View Institutional Ownership Trends for ResMed.

Which major investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Crossmark Global Holdings Inc., Congress Asset Management Co. MA, Professional Advisory Services Inc., SG Americas Securities LLC, Russell Investments Group Ltd., Copeland Capital Management LLC and LaFleur & Godfrey LLC. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, James Hollingshead, John P Wareham, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor. View Insider Buying and Selling for ResMed.

Which major investors are buying ResMed stock?

RMD stock was purchased by a variety of institutional investors in the last quarter, including WCM Investment Management LLC, First Trust Advisors LP, State Street Corp, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Maverick Capital Ltd., Voloridge Investment Management LLC and Man Group plc. View Insider Buying and Selling for ResMed.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $149.40.

How big of a company is ResMed?

ResMed has a market capitalization of $21.48 billion and generates $2.61 billion in revenue each year. The medical equipment provider earns $404.59 million in net income (profit) each year or $3.64 on an earnings per share basis. ResMed employs 7,240 workers across the globe.View Additional Information About ResMed.

What is ResMed's official website?

The official website for ResMed is http://www.resmed.com/.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]


MarketBeat Community Rating for ResMed (NYSE RMD)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  324 (Vote Outperform)
Underperform Votes:  595 (Vote Underperform)
Total Votes:  919
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel